Free morning briefing · 07:30 weekdays
The RNS that moves prices, in your inbox before the open.
AI-ranked movers and high-impact RNS across the FTSE 100, 250, SmallCap and AIM — one short email, every market day.
Get the briefing
SCLP

Scancell Holdings plc

SCLPLSEUnited KingdomHealthcareBiotechnologyFTSE AIM 100

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of…more

P/B-12.99x
£140.96M
Market Cap
EV: £111.91M
MOM10
QUAL4
VAL—
RSK9
SCLP
£140.96M
Market Cap · EV £111.91M

Scancell Holdings plc

MOM10
QUAL4
VAL—
RSK9

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of…more

Latest RNS from Scancell Holdings plc

All SCLP news → · RNS daily feed

Analyst consensus: Buy

As of 21 Sept 2026, 2 analysts rate Scancell Holdings plc a Buy, with 100% buy ratings and a mean price target of 26p (range 19p–32p), +163% vs the current price.

Strong buy: 0Buy: 2Hold: 0Sell: 0Strong sell: 0

Full analyst history →

More Healthcare companies